AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24184147 — intervention group
Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) in children (n=99)
Number of subjects: 153
Study 24184147 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) in adults
Number of subjects: 153
Study 23155007 — intervention group
Group type: EXPERIMENTAL
Intervention: W→G
Number of subjects: 512
Study 23155007 — intervention group
Group type: EXPERIMENTAL
Intervention: R→B
Number of subjects: 512
Study 23155007 — intervention group
Group type: EXPERIMENTAL
Intervention: G→B
Number of subjects: 512
Study 23155007 — intervention group
Group type: EXPERIMENTAL
Intervention: B→G
Number of subjects: 512
Study 23155007 — intervention group
Group type: EXPERIMENTAL
Intervention: W→B
Number of subjects: 512
Study 21058611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Process Model (DPM) intervention with both loss-orientation (LO) and restoration-orientation (RO) coping
Number of subjects: 298
Study 21058611 — intervention group
Group type: COMPARATOR
Intervention: Traditional grief groups focusing on loss-orientation (LO)
Number of subjects: 298
Study 17983336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Relaxation Response (RR)
Number of subjects: 119
Study 17983336 — intervention group
Group type: COMPARATOR
Intervention: Control (Acupuncture + Soft Music)
Number of subjects: 119
Study 14979891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions)
Number of subjects: 10
Study 14979891 — intervention group
Group type: COMPARATOR
Intervention: Control (10 subjects)
Number of subjects: 10
Study 11121919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral menadiol 20 mg o.d. for 3 days (n=12)
Number of subjects: 26
Study 11121919 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phytomenadione 10 mg o.d. for 3 days (n=14)
Number of subjects: 26
Study 9125681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine, 4 mg daily
Number of subjects: 17
Study 9125681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1607091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lavage plus enemas
Number of subjects: 0
Study 1607091 — intervention group
Group type: COMPARATOR
Intervention: Oral lavage alone
Number of subjects: 0
Study 2984617 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo Sampoon tablets
Number of subjects: 450
Study 2984617 — intervention group
Group type: COMPARATOR
Intervention: Collatex sponge
Number of subjects: 450
Study 2984617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 450
Study 3689613 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cimetidine 200 mg
Number of subjects: 20
Study 3689613 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ranitidine 50 mg
Number of subjects: 20
Study 31058387 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1462
Study 31058387 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in septic patients
Number of subjects: 1462
Study 31058387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of statins
Number of subjects: 1462
Study 28620941 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 75 g sucrose per day for 14 days
Number of subjects: 12
Study 23786500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention through hospital pharmacists
Number of subjects: 385
Study 23786500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 385
Study 22981342 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by 625 mg orally every 8h for 4 days
Number of subjects: 62
Study 22981342 — intervention group
Group type: COMPARATOR
Intervention: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by placebo orally at the same time intervals
Number of subjects: 62
Study 21544000 — intervention group
Group type: EXPERIMENTAL
Intervention: General + Specific Warm-Up (G + SWU)
Number of subjects: 13
Study 21544000 — intervention group
Group type: COMPARATOR
Intervention: Specific Warm-Up (SWU)
Number of subjects: 13
Study 18434903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.1 microg/kg/min started at surgical induction and continued for 48 hrs
Number of subjects: 79
Study 18434903 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg orally twice a day, from preoperative day 1 to postoperative day 1
Number of subjects: 79
Study 18434903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fenoldopam and N-acetylcysteine
Number of subjects: 79
Study 18434903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 79
Study 18434903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 79
Study 18434903 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 79
Study 17060807 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG with the position of electrodes marked on the skin using a dermographic pen
Number of subjects: 276
Study 17060807 — intervention group
Group type: COMPARATOR
Intervention: Traditional ECG without marking the position of electrodes
Number of subjects: 276
Study 15138096 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated aortic valve replacement with 23‐mm St. Jude Medical prosthetic valves and posterior aortic root enlargement
Number of subjects: 19
Study 15138096 — intervention group
Group type: COMPARATOR
Intervention: 19‐mm and 21‐mm St. Jude Medical prosthetic valves implanted without aortic root enlargement
Number of subjects: 19
Study 11075310 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD891 (60 micrograms/kg bolus dose + 336 micrograms/kg 8-h infusion)
Number of subjects: 2
Study 11075310 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD891 (various intravenous regimens)
Number of subjects: 2
Study 11075310 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD891
Number of subjects: 2
Study 11075310 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD039
Number of subjects: 2
Study 11075310 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD891 and RGD039
Number of subjects: 2
Study 11075310 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD891 with PPACK
Number of subjects: 2
Study 9146820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine
Number of subjects: 6
Study 9146820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg naloxone
Number of subjects: 6
Study 9146820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine and 0.1 mg naloxone in combination
Number of subjects: 6
Study 9146820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8398324 — intervention group
Group type: EXPERIMENTAL
Intervention: STADMAX (scopolamine, tavegyl, ativan, dexamethasone, high dose maxolon)
Number of subjects: 78
Study 8398324 — intervention group
Group type: EXPERIMENTAL
Intervention: STADMAX
Number of subjects: 78
Study 8398324 — intervention group
Group type: COMPARATOR
Intervention: SAD (serenace, ativan, dexamethasone, low dose maxolon)
Number of subjects: 78
Study 3490329 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 903
Study 3490329 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 903
Study 30244882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation above 60 Gy EQD2
Number of subjects: 59
Study 30244882 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent or sequential chemoradiation or radiation only
Number of subjects: 59
Study 27041406 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Number of subjects: 11
Study 27041406 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up open-label trial with telotristat etiprate
Number of subjects: 11
Study 27041406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24855132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine and vestibular rehabilitation (treatment group)
Number of subjects: 31
Study 24855132 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (control group)
Number of subjects: 31
Study 23315697 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (Megaforce)
Number of subjects: 3
Study 23315697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar-free lemonade)
Number of subjects: 3
Study 23315697 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 3
Study 20626608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg or 50 mg
Number of subjects: 0
Study 19039629 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg
Number of subjects: 106
Study 19039629 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 400 mg
Number of subjects: 106
Study 16866136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (400 mg)
Number of subjects: 368
Study 16866136 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg)
Number of subjects: 368
Study 16866136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (300 mg)
Number of subjects: 368
Study 16866136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (400 mg/day for 3 days)
Number of subjects: 368
Study 16866136 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for 3 days)
Number of subjects: 368
Study 16866136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (200 mg)
Number of subjects: 368
Study 16866136 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (200 mg)
Number of subjects: 368
Study 12810507 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment
Number of subjects: 14
Study 12810507 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated plaque)
Number of subjects: 14
Study 11015484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin A intake (high carotenoid intake)
Number of subjects: 8174
Study 11015484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A intake in infants up to 1 year old
Number of subjects: 8174
Study 11015484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A intake in children ≥3 years of age
Number of subjects: 8174
Study 8752294 — intervention group
Group type: COMPARATOR
Intervention: Monovalent WC3 reassortant vaccine (serotype G1)
Number of subjects: 0
Study 8752294 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent WC3 reassortant vaccine (HRV G1, G2, G3, and P[8])
Number of subjects: 0
Study 1572450 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis with a flowsplitter
Number of subjects: 117
Study 1572450 — intervention group
Group type: COMPARATOR
Intervention: Prosthesis with a 90 degrees bifurcation
Number of subjects: 117
Study 1572450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study 3931943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine infusion (0.1 microgram/kg/min)
Number of subjects: 6
Study 3931943 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 29534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service for 2 years
Number of subjects: 178
Study 29534765 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service for an additional 3 years
Number of subjects: 178
Study 29534765 — intervention group
Group type: COMPARATOR
Intervention: Regular care post-2 years of EI
Number of subjects: 178
Study 29902177 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term food assistance
Number of subjects: 469
Study 29902177 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cash transfers
Number of subjects: 469
Study 29902177 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (comparison arm)
Number of subjects: 469
Study 29902177 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 469
Study 27368012 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (double-low protocol): 100 kVp tube voltage with 40% ASIR, iodixanol at 270 mg I/mL
Number of subjects: 128
Study 27368012 — intervention group
Group type: COMPARATOR
Intervention: Group B: 120 kVp tube voltage with filtered back projection (FBP), iodixanol at 270 mg I/mL
Number of subjects: 128
Study 27368012 — intervention group
Group type: COMPARATOR
Intervention: Group C: 120 kVp tube voltage with FBP, ioversol at 350 mg I/mL
Number of subjects: 128
Study 24179072 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block (LBBB)
Number of subjects: 1151
Study 24179072 — intervention group
Group type: COMPARATOR
Intervention: No new-onset left bundle branch block (LBBB)
Number of subjects: 1151
Study 22972216 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment intervention (10 weekly hour-long sessions including group education and group discussion)
Number of subjects: 47
Study 22972216 — intervention group
Group type: COMPARATOR
Intervention: Control group (two-hour education about health management)
Number of subjects: 47
Study 19073755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2191
Study 17501758 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFN plus RBV (1000 mg if body weight <75 kg and 1200 mg if >75 kg)
Number of subjects: 348
Study 17501758 — intervention group
Group type: COMPARATOR
Intervention: pegIFN plus RBV (1000-1200 mg/day)
Number of subjects: 348
Study 17501758 — intervention group
Group type: COMPARATOR
Intervention: pegIFN plus RBV (800 mg/day)
Number of subjects: 348
Study 15357755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with liquid nitrogen (single freeze-thaw cycle)
Number of subjects: 90
Study 11448801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid/day
Number of subjects: 69
Study 11448801 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 69
Study 9569648 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicators describing traits in others
Number of subjects: 0
Study 9569648 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations influencing specific trait impressions of communicators
Number of subjects: 0
Study 9569648 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative processes in spontaneous trait transference
Number of subjects: 0
Study 9569648 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic stimuli in Study 4
Number of subjects: 0
Study 7920074 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-blocker therapy with famotidine
Number of subjects: 42
Study 7920074 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with bismuth, amoxicillin, and metronidazole
Number of subjects: 42
Study 7920074 — intervention group
Group type: COMPARATOR
Intervention: Persistent H. pylori infection
Number of subjects: 42
Study 7920074 — intervention group
Group type: COMPARATOR
Intervention: No persistent H. pylori infection
Number of subjects: 42
Study 3289930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 3289930 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended prophylactic nevirapine given daily from 6 weeks to 6 months
Number of subjects: 0
Study 31567725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall growth (not specified intervention)
Number of subjects: 0
Study 31567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0
Study 31567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Short breastfeeding duration
Number of subjects: 0
Study 31567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy exposure
Number of subjects: 0
Study 31567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimbabwe (location)
Number of subjects: 0
Study 27513639 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal Stimulation Therapy (PST) with boosters and home exercise program
Number of subjects: 60
Study 27513639 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) combined with home exercise program
Number of subjects: 60
Study 26813525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF) (25% fat)
Number of subjects: 53
Study 26813525 — intervention group
Group type: COMPARATOR
Intervention: Portion control diet (PC) (33% fat)
Number of subjects: 53
Study 25053182 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (LS) therapy
Number of subjects: 94
Study 25053182 — intervention group
Group type: COMPARATOR
Intervention: Standard inotropic therapy
Number of subjects: 94
Study 22423628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength-training and stretching-exercise group (CSSG, n = 49)
Number of subjects: 101
Study 22423628 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise group (SG, n = 52)
Number of subjects: 101
Study 22423628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CSSG and SG)
Number of subjects: 101
Study 19535709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized multimedia instruction
Number of subjects: 30
Study 19535709 — intervention group
Group type: COMPARATOR
Intervention: Personalized video‐assisted oral debriefing
Number of subjects: 30
Study 18781429 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 15215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 151
Study 15215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding high-fat foods intervention
Number of subjects: 151
Study 15215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing fiber intake intervention
Number of subjects: 151
Study 15215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising three times per week intervention
Number of subjects: 151
Study 15215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying pros for weight management
Number of subjects: 151
Study 15215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for choosing low-fat meals
Number of subjects: 151
Study 12038920 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT reported in 8 articles
Number of subjects: 359
Study 12038920 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR reported in 18 articles
Number of subjects: 359
Study 9642436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl at 40, 60, or 120 mg bid
Number of subjects: 588
Study 9642436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 9402777 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental trauma centre and regional trauma system
Number of subjects: 0
Study 9402777 — intervention group
Group type: COMPARATOR
Intervention: Control regions
Number of subjects: 0
Study 1783533 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (5 mg/kg loading dose over 10 minutes followed by 24-hour infusion at 3.5 mg/kg/h)
Number of subjects: 24
Study 1783533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6756362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% diacetyl nadolol
Number of subjects: 0
Study 6756362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diacetyl nadolol
Number of subjects: 0
Study 6756362 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 0
Study 6756362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nadolol
Number of subjects: 0
Study 30965275 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of progressive high intensity resistance training, 2 sessions per week, n = 16
Number of subjects: 30
Study 30965275 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of habitual lifestyle, n = 14
Number of subjects: 30
Study 27808410 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 5%)
Number of subjects: 993
Study 27808410 — intervention group
Group type: COMPARATOR
Intervention: Stable weight (< 5%)
Number of subjects: 993
Study 27808410 — intervention group
Group type: COMPARATOR
Intervention: Weight gain (≥ 5%)
Number of subjects: 993
Study 26091197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 50
Study 26091197 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavior Therapy (CBT)
Number of subjects: 50
Study 25957143 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified carotid sinus massage (CSM) using ultrasonography
Number of subjects: 30
Study 25957143 — intervention group
Group type: COMPARATOR
Intervention: Conventional carotid sinus massage (CSM)
Number of subjects: 30
Study 24016810 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 1116
Study 24016810 — intervention group
Group type: COMPARATOR
Intervention: Licensed trivalent influenza vaccine (TIV)
Number of subjects: 1116
Study 24016810 — intervention group
Group type: COMPARATOR
Intervention: Investigational trivalent influenza vaccine (TIV)
Number of subjects: 1116
Study 22123890 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV and PCV-7 (group 1)
Number of subjects: 1027
Study 22123890 — intervention group
Group type: COMPARATOR
Intervention: PCV-7 followed 6 weeks later by MMRV (group 2)
Number of subjects: 1027
Study 22123890 — intervention group
Group type: COMPARATOR
Intervention: MMRV followed 6 weeks later by PCV-7 (group 3)
Number of subjects: 1027
Study 18264759 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (prolonged treatment beyond 3 months)
Number of subjects: 182
Study 16368744 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 14
Study 16368744 — intervention group
Group type: COMPARATOR
Intervention: Control (age- and sex-matched)
Number of subjects: 14
Study 14730252 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel in combination with ASA
Number of subjects: 12000
Study 14730252 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term clopidogrel therapy
Number of subjects: 12000
Study 14730252 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended clopidogrel therapy
Number of subjects: 12000
Study 14730252 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel > or =6 h before PCI
Number of subjects: 12000